Treatment of C. difficile Infection

First-Line Treatment Recommendations

• The American College of Physicians recommends oral vancomycin as first-line treatment for initial episodes of C. difficile infection 1, 2
• The American College of Physicians recommends oral metronidazole as an alternative for mild-moderate initial episodes of C. difficile infection 1, 2
• Fidaxomicin is non-inferior to vancomycin with lower recurrence rates, though not first-line for uncomplicated disease due to cost 1

Rifaximin's Limited Role in C. difficile

• Rifaximin is only supported as adjunctive therapy for recurrent C. difficile infection after standard treatment with vancomycin or metronidazole, with anecdotal evidence supporting its use 1, 2
• The British Society of Gastroenterology recommends against rifaximin as primary therapy for colitis 6

Evidence for Adjunctive Use Only

• Rifaximin may have a role after vancomycin treatment in recurrent cases of C. difficile infection, with a retrospective series showing 53% of patients had no relapse at 12 weeks 1, 2

Recommended Treatment Algorithm

• For initial C. difficile infection, use oral vancomycin or metronidazole as first-line, and reserve fidaxomicin for high-risk recurrence cases 1, 2
• For multiple recurrences, consider vancomycin with pulsed or tapering courses, and rifaximin as adjunctive therapy only after vancomycin course 1, 2

Key Clinical Pitfalls

• Never use rifaximin as monotherapy due to the propensity for rapid resistance development and treatment failure 1, 2
• Rifaximin has no established role in severe/fulminant C. difficile colitis 1
• The drug's primary FDA approval is for IBS-D and travelers' diarrhea, not C. difficile 3, 4